title: Effects of interferon-beta in combination with 5-fluorouracil on the growth of esophageal cancer cells in vitro.
abstract: The possible antiproliferative potency of human recombinant interferon-beta (hIFN-beta) towards ten human esophageal cancer cell lines was examined in comparison with the activity of the factor towards human malignant melanoma cell lines. The cell growth of esophageal cancer cell lines was inhibited by hIFN-beta in a dose- and time- dependent manner. The 50% inhibitory concentrations (IC50) of hIFN-beta on nine cell lines out of ten ranged between 23 to 332 IU/ml of culture medium. The remaining cell line, T.Tn, was less sensitive to the interferon (IC50, 611 IU/ml). Under the same culture conditions, the melanoma cell lines tested differed markedly in their sensitivity to hIFN-beta. When the esophageal cancer cells were treated with 5-fluorouracil (5-FU) in the presence of a low concentration of hIFN-beta, the effectiveness of 5-FU was markedly enhanced. In particular, the rate of growth inhibition of T.Tn cells was more than the added potencies of 5-FU and hIFN-beta indicating that the interferon is an effective biomodulator of 5-FU. All these data suggest that combination therapy with hIFN-beta and the anticancer drug 5-FU would be beneficial for the treatment of carcinoma of the esophagus.
authors.affiliation: Department of Surgery II Nagoya University School of Medicine, Aichi, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Tsunoo
authors.forename: S
authors.initials: S
authors.lastname: Komura
authors.forename: N
authors.initials: N
authors.lastname: Ohishi
authors.forename: S
authors.initials: S
authors.lastname: Akiyama
authors.forename: Y
authors.initials: Y
authors.lastname: Kasai
authors.forename: K
authors.initials: K
authors.lastname: Ito
authors.forename: A
authors.initials: A
authors.lastname: Nakao
authors.forename: K
authors.initials: K
authors.lastname: Yagi
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004354:Drug Screening Assays, Antitumor; D004357:Drug Synergism; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005472:Fluorouracil / Q000008:administration & dosage; D006131:Growth Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D006801:Humans; D007371:Interferon-gamma / Q000008:administration & dosage / Q000494:pharmacology*; D011994:Recombinant Proteins; D014407:Tumor Cells, Cultured
chemical_list: D006131:Growth Inhibitors; D011994:Recombinant Proteins; D007371:Interferon-gamma; D005472:Fluorouracil